Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool Detects Early Signs of Blood Mutations Linked to Cancer and Heart Disease

By LabMedica International staff writers
Posted on 27 Aug 2025

Deep inside the body, clusters of mutated blood cells can slowly form without symptoms, affecting about one in five older adults. More...

This condition, known as clonal hematopoiesis of indeterminate potential (CHIP), increases the likelihood of leukemia more than tenfold and raises the risk of heart disease up to fourfold. Because it often goes undetected for years, finding CHIP earlier could allow for proactive monitoring or preventive care to reduce risk. Now, an artificial intelligence (AI) tool can find early signs of blood mutations linked to cancer and heart disease.

The AI tool called UNISOM—short for UNIfied SOmatic calling and Machine learning—has been developed by researchers at Mayo Clinic (Rochester, MN, USA) to identify CHIP-related mutations in standard genetic datasets. Unlike earlier methods that required advanced sequencing, this innovation allows clinicians and scientists to uncover subtle DNA changes using existing data, broadening research and potential clinical use.

UNISOM was evaluated in a study published in Genomics, Proteomics & Bioinformatics. The tool successfully detected nearly 80% of CHIP mutations using whole-exome sequencing, which focuses on protein-coding DNA. It also identified mutations present in fewer than 5% of blood cells when tested on whole-genome sequencing data from the Mayo Clinic Biobank, outperforming conventional techniques that often miss such small but significant changes.

By detecting CHIP at its earliest molecular stages, the approach offers a powerful new way to study disease progression and guide patient care. The researchers emphasized that integrating this tool into larger and more diverse datasets could strengthen predictions, enabling earlier detection of high-risk individuals and more precise treatment decisions in the clinic.

"We're engineering a path from genomic discovery to clinical decision-making," said Shulan Tian, Ph.D., the co-senior author and a bioinformatician at Mayo Clinic. "It's rewarding to help bring these discoveries closer to clinical care, where they can inform decisions and support more precise treatment."


New
Gold Member
Collection and Transport System
PurSafe Plus®
Collection and Transport System
PurSafe Plus®
New
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: LungCanSeek demonstrated an overall sensitivity of 83.5% and specificity of 90.3% in detecting lung cancer (Photo courtesy of AdobeStock)

New Blood Test Offers Affordable and Accurate Early Detection of Lung Cancer

Lung cancer remains the leading cause of cancer-related deaths worldwide, largely because most cases are diagnosed at advanced stages when treatment options are limited. Early detection significantly improves... Read more

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The TriVerity IVD test includes the TriVerity cartridge and the Myrna instrument (Photo courtesy of Inflammatix)

Blood-Based Immune Cell Signatures Could Guide Treatment Decisions for Critically Ill Patients

When a patient enters the emergency department in critical condition, clinicians must rapidly decide whether the patient has an infection, whether it is bacterial or viral, and whether immediate treatment... Read more

Industry

view channel
Image: The collaboration supports clinical validation and regulatory submissions of the new T1D 4-plex assay on Revvity’s GSP instrument (Photo courtesy of Revvity)

Revvity and Sanofi Collaborate on Program to Revolutionize Early Detection of Type 1 Diabetes

Type 1 diabetes (T1D) is a lifelong autoimmune condition in which the immune system destroys the pancreas’s insulin-producing beta cells, leading to dependence on insulin therapy. Early detection is critical... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.